|Home||» Products||» Active Pharmaceutical Ingredients (API)||» Tigecycline|
We have garnered a niche for ourselves in this domain by offering an unmatched range of Tigecycline. These tablets are recommended for treating complicated Intra-abdominal infections, skin infections, community-acquired pneumonia and acute myeloid leukemia. In order to process Tigecycline, we use best quality ingredients at our modern labs, as per the standards laid down by regulatory bodies. Our clients can avail these drugs from us at a pocket friendly price.
IUPAC NAME : N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl]-2-(tert-butylamino)acetamide
CAS Number : 220620-09-7
Therapeutic Category: Antibiotic
Innovator: Developed by Francis Tally and marketed by Wyeth under the brand name Tygacil
Indication : Tigecycline is given intravenously and has activity against a variety of Gram-positive and Gram-negative bacterial pathogens, many of which are resistant to existing antibiotics
Dosage: 50mg in 1 vial injection.
Class: New class of antibiotics called the glycylcyclines
This antibiotic is the first clinically available drug in a new class of antibiotics called the glycylcyclines. It is structurally similar to the tetracyclines in that it contains a central four-ring carbocyclic skeleton and is actually a derivative of minocycline. Tigecycline has a substitution at the D-9 position which is believed to confer broad spectrum activity.
Mechanism of Action:
Tigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
Tigez ( 50mg) 1 vial Ã¢â¬â Lupin Laboratories